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Lichen planus pemphigoides is an autoimmune sub-
epidermal blistering disease. The finding of immuno-
globulin G antibodies directed against the basement
membrane zone differentiates it from bullous lichen
planus. The aim of this study was to identify the target
antigen of lichen planus pemphigoides autoantibodies.
Sera from lichen planus pemphigoides patients (n J 4)
stained the epidermal side of NaCl-split human skin
in a pattern indistinguishable from that produced by
bullous pemphigoid sera. In bullous pemphigoid, the
autoimmune response is directed against BP180, a
hemidesmosomal transmembrane collagenous glyco-
protein. We previously demonstrated that bullous
pemphigoid sera predominantly react with a set of
four epitopes (MCW-0 through MCW-3) clustered
within a 45 amino acid stretch of the major noncolla-
genous extracellular domain (NC16A) of BP180. By
immunoblotting and enzyme-linked immunosorbent
assay, lichen planus pemphigoides sera were also
strongly reactive with recombinant bullous pem-
The term ‘‘lichen ruber pemphigoides’’ or lichen planuspemphigoides (LPP) was first used by Kaposi in 1892for a disease characterized by lichen planus (LP) lesionsand numerous bullae (Kaposi, 1892). In addition toclinical and histologic criteria, immunofluorescence
microscopic findings are crucial in distinguishing between bullous
LP and LPP. In bullous LP, blisters are confined to LP lesions and
are a consequence of severe basal cell degeneration, as found on
histopathology. In contrast, bullous lesions in LPP follow the
appearance of papules and plaques and may be found on both LP
lesions and previously unaffected skin. In LPP, light microscopy
shows the typical features of LP in papular lesions and changes of
bullous pemphigoid in lesional biopsies of blistered skin. Most
Manuscript received November 24, 1998; revised February 22, 1999;
accepted for publication March 9, 1999.
Reprint requests to: Dr. Detlef Zillikens, Department of Dermatology,
University of Wu¨rzburg, Josef-Schneider-Str. 2, 97080 Wu¨rzburg,
Germany.
Abbreviations: BP, bullous pemphigoid; GST, glutathione S-transferase;
IB, immunoblot; LP, lichen planus; LPP, lichen planus pemphigoides.
0022-202X/99/$14.00 · Copyright © 1999 by The Society for Investigative Dermatology, Inc.
117
phigoid 180 NC16A. The lichen planus pemphigoides
epitopes were further mapped using a series of over-
lapping recombinant segments of the NC16A domain.
All lichen planus pemphigoides sera reacted with
amino acids 46–59 of domain NC16A, a protein seg-
ment that was previously shown to be unreactive
with bullous pemphigoid sera. Two lichen planus
pemphigoides sera, in addition, reacted with the
immunodominant antigenic region associated with
bullous pemphigoid. In conclusion, there are now five
bullous diseases that are associated with an auto-
immune response to BP180: bullous pemphigoid;
pemphigoid/herpes gestationis; cicatricial pem-
phigoid; linear immunoglobulin A disease; and lichen
planus pemphigoides. In addition, we have identified
a novel epitope within the BP180 NC16A domain,
designated MCW-4, that appears to be uniquely recog-
nized by sera from patients with lichen planus pem-
phigoides. Key words: autoantigen/collagen/epitope/
hemidesmosome. J Invest Dermatol 113:117–121, 1999
importantly, the finding of linear deposits of immunoglobulin (Ig)G
and/or C3 at the basement membrane zone (BMZ) in perilesional
skin differentiates LPP from bullous LP (Stingl and Holubar, 1975;
Hintner et al, 1979; Lang and Maize, 1983; Willesteed et al, 1991).
The clinical and immunologic observations associated with bulla
formation in LPP are similar to findings in bullous pemphigoid
(BP), an autoimmune subepidermal blistering disease of the elderly
that is also characterized by the presence of autoantibodies to the
BMZ (reviewed by Zillikens et al, 1996a). Antibodies in BP are
directed to two hemidesmosomal proteins, BP180 and BP230
(Stanley et al, 1981, 1988; Labib et al, 1986; Diaz et al, 1990).
BP230 is located within the intracellular hemidesmosomal plaque
(Tanaka et al, 1990), whereas BP180 is a transmembrane glycopro-
tein with a long extracellular tail that spans the lamina lucida of
the BMZ (Giudice et al, 1992; Li et al, 1993; Bedane et al, 1997;
Masunaga et al, 1997; Zillikens and Giudice, 1999). Data from a
passive transfer mouse model strongly suggest the pathogenic
relevance of antibodies to BP180 (Liu et al, 1993; Giudice et al,
1995). Epitope mapping studies have shown that the NC16A
domain of human BP180 harbors the major extracellular antigenic
sites recognized by BP sera (Giudice et al, 1993; Zillikens et al,
1997a). Further, NC16A was shown to contain four distinct BP-
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Table I. Clinical and immunofluorescence findings in LPP patientsa
LPP-KN LPP-NO LPP-DA LPP-PA
Age 52 43 61 34
Sex F M F F
Race Caucasian Caucasian African Caucasian
Direct IF C3 , IgG C3 IgG, C3 IgG, C3
Indirect IF titerb 1:80 1:80 1:320 1:160
Clinical features Generalized lichenoid papules; Verrucous papules and plaques Pruritic violaceus verrucous Violaceus papules on trunk,
blisters on dorsal aspects of on the dorsum of the hands papules disseminated over lower arms, legs, and feet;
hands and feet and wrists; vesiculae and bullae trunk, buttocks, thighs; vesicles bullae on thighs and feet
on thighs, lower legs, abdomen on thighs
and arms
Treatment Clearance of blisters with oral Clearance with oral Clearance with topical Clearance with tapering oral
prednisone—initially 100 mg, prednisone—initially 60 mg, corticosteroids corticosteroids over 8 wk
tapering over 2 wk; treatment tapering over 4 wk
of LP with oral psoralen
ultraviolet A
aAll patients showed white streaks on buccal mucosa.
bIndirect IF was performed on 1 M NaCl-split human skin.
associated epitopes – all of which are clustered within the N-
terminal 45 amino acid stretch of this protein domain (Zillikens
et al, 1997a). Using the NC16A domain as the target antigen,
sensitive immunoblot (Matsumura et al, 1996) and enzyme-linked
immunosorbent assay (ELISA) techniques (Zillikens et al, 1997b)
for the detection of anti-BP180 autoantibodies in the sera of BP
patients have recently been developed. In addition to the NC16A
domain, autoantibodies may react with other antigenic sites on the
extra-and intracellular domains of BP180 (Balding et al, 1996;
Murakami et al, 1998; Pierrard et al, 1999; Nie and Hashimoto,
1999). Whereas an argument can be made that LPP is merely the
coexistence of two diseases, LP and BP, there are several clinical
observations that support the concept that LPP represents a clinical
entity distinct from either LP or BP. The mean age of our LPP
patients is 48 y, which is in contrast to the mean age of 75 y in
the 115 BP patients treated at the University of Wu¨rzburg over
the past 10 y (Kippes et al, 1999). In contrast to BP, bullous lesions
in LPP are preceded by papules and plaques. In addition, LPP
appears to show a considerably better response to treatment
compared with BP (Bouloc et al, 1998). Finally, as reported in this
paper, we now have immunologic data that distinguishes LPP from
BP at the epitope level.
Previous studies to characterize the autoantigen in LPP have
yielded conflicting results. Okada et al (1986) reported LPP autoanti-
bodies to a 240 kDa protein also recognized by antibodies in BP.
Subsequently, LPP sera were found to react with the two major
BP antigens, BP180 and BP230, as well as a unique band at
200 kDa (Davis et al, 1991; Tamada et al, 1995; Ogg et al, 1997;
Bouloc et al, 1998). In this study, we used recombinant forms of
BP180 to determine whether this autoantigen was indeed a target
of LPP autoantibodies. We found that LPP sera, like BP sera, label
the epidermal side of salt-split skin and react with the NC16A
domain of BP180. In contrast to BP, however, LPP sera recognized
a novel epitope located on the C-terminal portion of the NC16A
domain of BP180.
MATERIALS AND METHODS
Patients and sera Skin and serum samples were obtained from 4 well
characterized LPP patients. Clinical features of the patients are summarized
in Table I. In all patients, LP lesions preceded the formation of blisters
which occurred on both involved and uninvolved skin. Biopsies from
papular lesions showed typical changes of LP histologically and the presence
of cytoid bodies by direct immunofluorescence (IF). Histopathological
examination of biopsies from blistered skin revealed subepidermal vesicula-
tion. Direct IF microscopy of skin biopsies taken from sites immediately
adjacent to bullae showed linear deposits of IgG and/or C3 at the BMZ.
Indirect IF analysis on 1 M NaCl-separated human skin was performed as
described previously (Zillikens et al, 1996b).
Figure 1. Schematic diagram of BP180 and recombinant forms of
the NC16A domain used in this study. TM, transmembrane domain;
the NC16A domain has been subdivided into five regions each of
approximately 15 amino acids in length. Each of the fusion proteins
contains an N-terminal GST moiety. Amino acid residue numbers are
shown above the boxes.
Preparation of recombinant proteins DNA segments encoding the
entire NC16A domain and various fragments thereof (Fig 1) were obtained
by polymerase chain reaction amplification using a previously cloned
human BP180 cDNA as template (Giudice et al, 1992, 1993; Zillikens
et al, 1997a). The amplification products were subcloned into the BamHI/
EcoRI sites of pGEX-2T (Pharmacia, Piscataway, NJ). The resulting
glutathione S-transferase (GST)-BP180 fusion proteins and recombinant
GST were expressed in Escherichia coli strain DH5α and purified by
glutathione–agarose affinity chromatography, as described (Giudice et al,
1993; Zillikens et al, 1997a).
Immunoblotting of recombinant proteins and skin extracts
Sodium dodecyl sulfate–polyacrylamide gel electrophoresis and immunob-
lotting were performed as reported (Zillikens et al, 1996b). Epidermal and
dermal extracts were prepared as described (Labib et al, 1986; Zillikens
et al, 1996b) and fractionated on 6% and 5% protein gels, respectively,
whereas affinity-purified bacterial fusion proteins were fractionated on 15%
gels. To eliminate reactivity with the GST moiety of the fusion proteins,
sera of patients and controls were preadsorbed with a bacterial cell lysate
containing recombinant GST prior to labeling of immunoblots.
ELISA for recombinant GST and GST-NC16A To determine ELISA
reactivity with BP180 NC16A, we used a recently developed procedure
(Zillikens et al, 1997b). Briefly, each well of a standard 96-well microtiter
plate was coated with 400 ng of purified recombinant GST-NC16A1–5.
Each well was then incubated with 50 µl of primary serum (LPP, BP, or
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Figure 2. LPP sera react with the epidermal side of NaCl-split
human skin. One mole per liter NaCl-separated human skin was reacted
with serum of patient LPP-KN, followed by a second incubation with
fluorescein isothiocyanate-labeled goat anti-human IgG. Scale bar: 100 µm.
control) diluted 200-fold in phosphate-buffered saline, pH 7.2, containing
1% bovine serum albumin and 0.05% Tween-20 (Sigma, Diesenhofen,
Germany), followed by an incubation with horseradish peroxidase-labeled
goat anti-human IgG (Kirkegaard and Perry, Gaithersburg, MD) diluted
10,000-fold in phosphate-buffered saline, with 1% bovine serum albumin
and 0.05% Tween-20. After substrate addition, the optical density (OD)
of the reaction solution was measured at a wavelength of 492 nm. Each
serum was assayed in triplicate for reactivity with both GST-NC16A1–5
and recombinant GST. For each serum tested, the mean OD reading
obtained with GST was subtracted from the mean reading obtained with
GST-NC16A1–5. To minimize plate-to-plate variability, each ELISA plate
included the same four internal controls as described (Zillikens et al, 1997b).
Immunoadsorption procedures Immunoadsorptions were performed
using a liquid phase protocol as described previously (Zillikens et al, 1997a).
Diluted sera (1:100) were incubated overnight with recombinant GST or
with one of the GST fusion proteins containing various segments of the
NC16A domain. The mixtures were then centrifuged at 10,000 3 g for
15 min at 4°C. Immunoadsorptions were verified to be complete by the
absence of immunoblot reactivity with the recombinant protein that had
been used as the immunoadsorbent.
RESULTS
LPP sera react with the epidermal side of 1 M NaCl-split
skin All LPP sera included in this study revealed circulating IgG
autoantibodies binding to the epidermal side of NaCl-split skin
(Fig 2). Antibody titers ranged from 1:80 to 1:320 (Table I). No
circulating IgA or IgM antibodies were detected. The pattern of
indirect IF reactivity was the same as in two control BP sera. Two
sera from patients with epidermolysis bullosa acquisita reacted with
the dermal side of the split (data not shown).
Three of four LPP sera react with BP180 extracted from
epidermis To characterize further these anti-BMZ antibodies in
LPP sera, we performed immunoblot (IB) studies using epidermal
and dermal extracts. Three LPP sera reacted with BP180 extracted
from epidermis. No reactivity was found with BP230. By IB
analysis against a dermal extract, the two control EBA sera labeled
type VII collagen whereas, LPP and normal control sera showed
no specific reactivity (data not shown).
LPP sera react with recombinant BP180 NC16A by immuno-
blot analysis and ELISA To study reactivity of LPP sera with
the BP180 NC16A domain, we preadsorbed the sera against
recombinant GST and assayed them by IB analysis against affinity-
purified GST-NC16A. All four LPP sera, like the BP control sera,
reacted with this region of BP180 (Fig 3). This reactivity was
confirmed by ELISA. Autoantibodies to BP180 NC16A were
detected at levels above the cut-off of the ELISA (mean of control
sera plus 3 SD) in all LPP sera (Table II).
Figure 3. LPP sera react with the immunodominant NC16A domain
of BP180. GST-NC16A1–5 was fractionated by 15% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis, transferred to nitrocellulose, and
reacted with a BP serum (lane 1), sera from LPP-KN, LPP-NO, LPP-DA,
and LPP-PA (lanes 2–5), and a normal control (NC) serum (lane 6). All
sera were completely preadsorbed against recombinant GST. The migration
positions of molecular weight markers of 45, 31, and 21 kDa are shown
at the right.
Table II. LPP sera react with an epitope in region 4 of the
NC16A domain of BP180
LPP Patients
LPP-KN LPP-NO LPP-DA LPP-PA
BP180NC16A1–5 1 1 1 1 1 1 1
ELISAa 0.82b 0.75 0.47 0.9
IB reactivity with:
NC16A1c – – – –
NC16A2c – – 1 –
NC16A2.5c – 1 1 –
NC16A3c – 1 – –
NC16A1–3c – 1 1 –
NC16A4d 1 1 1 1 1 1
NC16A5d – – – –
a1:200 dilutions of LPP sera were assayed in triplicate against affinity-purified
forms of GST-NC16A and recombinant GST. The mean OD492 reading was
subtracted from the mean reading for GST-NC16A1–5.
bNumbers indicate the results of the OD492 reading. The cut-off for the ELISA
was set at an OD492 reading of 0.43 (mean of controls plus 3 SD).
c1:100 dilutions of LPP sera were reacted by immunoblot analysis against GST fusion
proteins containing NC16A1, NC16A2, NC16A2.5, NC16A3, and NC16A1–3.
dImmunoblot reactivity with NC16A4 and NC16A 5 was assessed indirectly as
explained in the text and demonstrated in Fig 5. After preadsorption of 1:100
dilutions of LPP sera against NC16A1–3, the sera continued to react with
NC16A1–5. This reactivity was completely abolished after preadsorption of the LPP
sera with NC16A2–4, demonstrating the presence of an epitope within NC16A4
and the absence of such in NC16A5.
Within the BP180 NC16A domain, LPP sera show a different
pattern of reactivity compared with BP sera To characterize
the antigenic sites recognized by LPP sera within the NC16A
domain, we performed an IB analysis using the following six
subregions of NC16A (Fig 4): region 1 (GST-NC16A1; lane 2),
region 2 (GST-NC16A2; lane 3), the junctions of regions 2 and 3
(GST-NC16A2.5; lane 4), region 3 (GST-NC16A3; lane 5), regions
1 through 3 (GST-NC16A1–3; lane 6), and the entire NC16A
domain (GST-NC16A1–5; lane 7). Equal mass amounts of the
various recombinant proteins were used for this analysis. All sera
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Figure 4. LPP sera show different reactivity with recombinant
forms of BP180 NC16A compared with BP sera. Recombinant
proteins were fractionated by 15% sodium dodecyl sulfate–polyacrylamide
gel electrophoresis, transferred to nitrocellulose, and labeled with BP (BP-
VI) and LPP sera (LPP-KN and LPP-PA). The three immunoblots shown
in this figure contained the same loadings of recombinant, affinity-purified
proteins: GST (lane 1) and fusion proteins NC16A1, NC16A2, NC16A2.5,
NC16A3, NC16A1–3, and NC16A1–5 (lanes 2–7, respectively). The
migration positions of molecular weight markers of 45, 31, 21, and 14 kDa
are shown at the right.
Figure 5. Autoantibodies in LPP sera react with an epitope located
in region 4 of BP180 NC16A. Recombinant proteins were fractionated
by 15% sodium dodecyl sulfate–polyacrylamide gel electrophoresis,
transferred to nitrocellulose, and labeled with two LPP sera [LPP-NO in
(a)–(c) and LPP-PA in (d)–(f)]. Parts (a) and (d) contained same protein
loadings, likewise (b) and (e) and (c) and (f). Fusion protein GST-NC16A
was loaded in lanes 2, 4, 6, 8, 10, and 12. Lanes 1 and 3 contained GST-
NC16A1–3, lanes 5 and 7 GST-NC16A2–4, and lanes 9 and 11 GST-
NC16A-2–5. Lanes 1, 2, 5, 6, 9, and 10 were incubated with LPP sera
preadsorbed with recombinant GST. Lanes 3 and 4 were incubated
with sera preadsorbed against GST-NC16A1–3, lanes 7 and 8 with sera
preadsorbed against GST-NC16A2–4, and lanes 11 and 12 with sera
preadsorbed against GST-NC16A2–5. The migration positions of molecular
weight markers of 45 and 31 kDa are shown at the right.
were preadsorbed against recombinant GST to eliminate reactivity
with the GST moiety of the fusion protein. GST was included in
each immunoblot assay (lane 1) to demonstrate that this adsorption
was complete. All LPP sera, like BP control sera, reacted with
GST-NC16A1–5. No serum reacted with region 1, one serum
with region 2, two sera with region 2.5, and one serum with
region 3. Interestingly, in contrast to BP sera, sera from LPP-KN
and LPP-PA did not react with GST-NC16A1–3, and a serum
from LPP-NO revealed lower reactivity with NC16A1–3 compared
with reactivity with NC16A1–5 as demonstrated in Table II. Sera
from LPP-KN and LPP-PA showed no reactivity with any of the
N-terminal fragments of NC16A (Fig 4).
LPP sera react with a novel epitope within the NC16A
domain of BP180 To identify further the binding sites of LPP
sera, we assayed for reactivity against the NC16A domain after
depleting the sera of reactivity with certain subfragments of this
BP180 domain. The immunodepletion was accomplished by a
liquid phase preadsorption of the sera with affinity-purified BP180
fusion proteins. Representative results of this analysis are shown in
Fig 5. After preadsorption with the control protein, GST, all four
of the LPP sera showed reactivity with the fusion protein containing
the full-length NC16A domain (GST-NC16A1–5), as well as with
GST-NC16A2–4, and GST-NC16A2–5; two LPP sera reacted
with GST-NC16A1–3 (lanes 1, 2, 5, 6, 9, 10). After depletion of
reactivity with GST-NC16A1–3, all four of the LPP sera retained
their reactivity with full-length NC16A (lanes 3 and 4), indicating
that the LPP sera reacted with one or more epitopes located on
regions 4 and/or 5 of NC16A. After preadsorption with either
GST-NC16A2–4 or GST-NC16A2–5, however, all four of the
LPP sera lost the ability to bind to the full-length NC16A domain
(lanes 7, 8, 11, 12). Thus, there was no detectable reactivity of any
of the LPP sera with either regions 1 or 5. Taken together, these
results indicate that all four of the LPP sera included in this study
contained antibodies that reacted with the 14 amino acid protein
segment designated region 4 of the BP180 NC16A domain.
DISCUSSION
The initial phase of this investigation into the autoimmune response
in LPP involved the analysis of sera from four well characterized
LPP patients by indirect IF on human skin sections and by IB
using a human epidermal extract as the antigen source. By both of
these techniques, the LPP sera showed reactivity patterns similar
to those exhibited by BP sera, i.e., linear IgG staining of the BMZ
and reactivity with a 180 kDa epidermal antigen which comigrated
with BP180. To determine more rigorously whether BP180 was
indeed the target antigen of LPP autoantibodies, these sera were
assayed for reactivity with recombinant forms of human BP180.
Like sera from most BP patients, LPP sera were shown to react
with the immunodominant NC16A domain of BP180. As reported
previously for BP sera (Zillikens et al, 1997b), we found that IB
and ELISA protocols using recombinant BP180 NC16A as the
target antigen were more sensitive than IB with epidermal extracts
for detecting anti-BP180 autoantibodies.
Interestingly, when the fine specificities of LPP autoantibodies
were further defined by epitope mapping analysis, it was uncovered
that LPP sera exhibited a reactivity pattern distinct from those of
BP sera. We previously demonstrated that autoantibodies in BP
react with a tightly clustered set of four epitopes within the N-
terminal 45 amino acids of the NC16A domain of BP180 (designated
MCW-0, MCW-1, MCW-2, and MCW-3; Zillikens et al, 1997b).
These BP-related antigenic sites correspond to regions 1 through
3 of NC16A. No reactivity with regions 4 or 5 have been detected
in BP sera. Importantly, all LPP sera included in this study reacted
with an epitope in region 4. This region comprises amino acids
46–59 of the NC16A domain. We propose to designate this novel
epitope MCW-4. In two LPP patients, MCW-4 was the only
antigenic site targeted within NC16A. The remaining two patients,
in addition, recognized BP-related epitopes in regions 2 and 3.
One can only speculate on reasons for the differences in reactivity
patterns of autoantibodies in BP and LPP. An interesting hypothesis
has been that the lichenoid infiltrate leading to damage and
degeneration of basal keratinocytes in LP may induce the production
of antibodies to the BMZ (Stingl and Holubar, 1975). In fact, the
inflammatory process in LP lesions, possibly on a certain human
leukocyte antigen background, may trigger an autoimmune response
to a different site on BP180 compared with the site recognized by
autoantibodies in BP. It remains possible that the autoimmune
responses to BP180 that are associated with BP and LPP involve
distinct pathogenic mechanisms. LPP patients of this study came
from a similar ethnic background as BP patients included in a
previous epitope mapping study (Zillikens et al, 1997a). Therefore,
it is unlikely that ethnic differences account for the different
reactivity with BP180 in LPP compared with BP.
In contrast to previously published reports (Davis et al, 1991;
Ogg et al, 1997; Bouloc et al, 1998), we found no evidence of
reactivity of LPP autoantibodies with antigens of 200 kDa, 230 kDa,
or 240 kDa. These observed immunologic differences could be
due to a heterogeneity of the autoimmune response in this disease.
It is also quite possible, however, that these differences are merely
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due to technical variation, e.g., differences in the methods used to
prepare the antigen extracts or differences in the conditions of the
immunologic assays. One recently reported case of LPP does
provide evidence for heterogeneity of the autoimmune response
among LPP patients (Bouloc et al, 1998). The serum of this LPP
patient bound to the dermal side of NaCl-split skin; whereas, LPP
sera in this study, as well as those previously reported, label the
epidermal side of the split. The target antigen in this recently
described patient remained uncharacterized, but from the indirect
IF result, it is highly unlikely that the BP180 NC16A domain is
targeted in this patient. It was suggested that the clinical phenotype
of LPP might be caused by antibodies to different components of
the BMZ (Bouloc et al, 1998). This is similar to the situation found
in patients with the clinical phenotype of cicatricial pemphigoid,
where autoantibodies may be directed to BP180 or laminin
5 (Bernard et al, 1992; Domloge-Hultsch et al, 1992; Balding
et al, 1996).
In summary, we demonstrate that BP180 is the target of LPP
autoantibodies binding to the epidermal side of NaCl-split skin.
Like sera from most BP patients, LPP sera react with the immuno-
dominant NC16A domain of BP180. Within the NC16A domain,
LPP sera recognize a novel epitope located at the C-terminal
portion of NC16A. Altogether, there are now five autoimmune
subepidermal bullous diseases in which BP180 has been shown
to be the target: BP; pemphigoid/herpes gestationis; cicatricial
pemphigoid; linear IgA disease (Zone et al, 1998); and LPP.
Future investigations will address the hypothesis that fine specificity
differences in autoantibodies could account for the clinical hetero-
geneity seen in patients with these various diseases.
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